Barrett’s esophagus with indefinite dysplasia (IND) represents a challenging diagnostic category, characterized by histologic uncertainty between nondysplastic Barrett’s esophagus and low-grade dysplasia. This ambiguity often arises due to overlapping features and confounding factors such as inflammation or technical issues during biopsy interpretation.
Barrett’s esophagus with indefinite dysplasia (IND) represents a challenging diagnostic category, characterized by histologic uncertainty between nondysplastic Barrett’s esophagus and low-grade dysplasia. This ambiguity often arises due to overlapping features and confounding factors such as inflammation or technical issues during biopsy interpretation. IND is considered a "gray zone" diagnosis with significant variability in pathologic interpretation among different pathologists, leading to inconsistent clinical management.
Patients with IND are at risk of harboring undetected dysplasia, underscoring the importance of early re-evaluation through repeat endoscopy after optimizing acid suppression. Persistent IND over time signals a meaningful risk of progression to higher-grade dysplasia or esophageal adenocarcinoma, necessitating careful surveillance and potentially more aggressive management strategies. High-quality endoscopic techniques, systematic biopsy protocols, and improved training for endoscopists are critical to reducing missed dysplasia and ensuring accurate diagnosis.
Emerging technologies, such as artificial intelligence-based computer-aided detection systems, show promise in enhancing the recognition of Barrett’s-related neoplasia. Additionally, risk stratification beyond histology, incorporating clinical factors and biomarkers, may help identify IND patients at highest risk for progression. Given the progression risk comparable to low-grade dysplasia, closer surveillance and selective therapeutic interventions are increasingly justified for patients with IND to mitigate the risk of advanced disease.
Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may...
Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological...
Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving...
Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice,...
Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and...
Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.